|Day Low/High||445.15 / 465.79|
|52 Wk Low/High||271.37 / 518.00|
Amid dramatically rising jobless claims, the Fed continues to fire big bullets, the Senate is pushing its economic support package and Gilead and Regeneron have made progress on coronavirus treatments.
Here again is my approach and my three stock groups: 'rebound', 'revenue' and 'virus'.
We looked at the charts of REGN yesterday but with things (read: stock prices) changing so fast it wouldn't hurt to look again.
I am pretty well covered in my 'virus group'. I could definitely see bringing a few shares of REGN on board the next time the algorithms include that name in a broad selloff. Not before.
The biopharma giant's work on a coronavirus antibody treatment is helping move its shares in a different direction than the market has taken.
The race is on. The prize could be countless lives saved and perhaps billions of dollars in revenue.
Biotech name has bolted higher with some amazing relative strength.
Amid a flood of corporate warnings over the coronavirus, all the major stock market indexes finished last month down 6.4% to 10.1%.
But don't throw up your arms yet -- here are names that could be golden opportunities.
The biopharma giant could fall further, so wait for a candlestick reversal pattern before going long.
Are the technical and quantitative approaches on the same page?
Now, many Real Money Post Industrial Average stocks should see a boost from the holiday splurge by shoppers.
The RMPIA's 3.8% jump even beat the Nasdaq Composite Index's 3.7% October climb.
RMPIA is up 20.9% in the first nine months of 2019.
Sure, Celgene, in its tie-up with Bristol-Myers Squibb, had to sell to meet merger requirements, but look at the future pay off for Amgen.
In July, the RMPIA climbed 0.6%, bringing its year-to-date return to just over 21%.
There are a number of RMPIA companies that will be beneficiaries of Back to School and holiday spending.
These bearish bets are showing both technical and quantitative deterioration.
Ironically, some experts now see biotech as a safe haven as the sector remains unaffected by trade wars and other global headwinds.
RMPIA outperformed once gain during April.
Netflix is bullish, but faces key resistance before it can make a big run higher.
A low-risk countertrend options trade may be worth a look in this name.
In this day and age, companies must be 'disruptors' or get left in the dust.
So far 2019 is proving to be a year where things have a habit of working out right.
It seemed just a matter of time before M&A returned to the biotech industry with a vengeance.